Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.73 |
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2361177 | 0.90 | SIGMAR1 (0.73) | SIGMAR1CCR3DRD2GRIN2DGRIN3B | |
| SCHEMBL4216497 | 0.86 | SIGMAR1 (0.74) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL12488997 | 0.85 | SIGMAR1 (0.73) | SIGMAR1AVPR1ADRD2GRIN2DGRIN3B | |
| SCHEMBL30281158 | 0.85 | SIGMAR1 (0.73) | SIGMAR1AVPR1ADRD2GRIN2DGRIN3B | |
| SCHEMBL747866 | 0.84 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL6314091 | 0.83 | SIGMAR1 (0.97) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL20955688 | 0.82 | SIGMAR1 (0.60) | SIGMAR1CCR3DRD2GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL20955046 | 0.81 | SIGMAR1 (0.67) | SIGMAR1AVPR1ADRD2GRIN2DGRIN3B | |
| SCHEMBL13610427 | 0.80 | AVPR1A (0.57) | SIGMAR1AVPR1A | |
| SCHEMBL14349499 | 0.79 | AVPR1A (0.60) | SIGMAR1AVPR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664216-B2 | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2356123-B1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2012-10-03 | — | — | EP | disclosed |
| EP-2356123-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010054961-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | SIGMAR1 238/4885CCR3 1423/4885AVPR1A 39/4885 |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | AVPR1A, OXTR, AVPR1B | SIGMAR1 123/4885CCR3 2224/4885AVPR1A 1/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | SIGMAR1 194/4885CCR3 1494/4885AVPR1A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.